Ionis pharmaceuticals inc IONS.US Overview Analysis
IONS AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
IONS Current Performance
3.09%
Ionis pharmaceuticals inc
2.24%
Avg of Sector
0.40%
S&P500
Top 10 High Relevance to IONS
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
ALNY | Alnylam pharmaceuticals, inc. | 3 | 5 | 4 | 3 | 1 | |
CLDX | Celldex therapeutics, incorporation | 2 | 2 | 1 | 2 | 1 | |
CHRO | Chromocell therapeutics corp | - | 2 | 2 | - | 1 | |
KNSA | Kiniksa pharmaceuticals ltd | 4 | 5 | 2 | 1 | 1 | |
AGIO | Agios pharmaceuticals inc | 3 | 3 | 3 | 2 | 1 |
- ALNY Alnylam pharmaceuticals, inc.Value 3Trend 5Swing Trading 4Whale Interest 3Dividend 1See more
IONS Profile
Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company's products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).